Financial Contrast: Zura Bio (NASDAQ:ZURA) & CG Oncology (NASDAQ:CGON)

CG Oncology (NASDAQ:CGONGet Free Report) and Zura Bio (NASDAQ:ZURAGet Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.

Profitability

This table compares CG Oncology and Zura Bio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CG Oncology N/A N/A N/A
Zura Bio N/A -28.83% -22.91%

Analyst Ratings

This is a breakdown of current ratings and price targets for CG Oncology and Zura Bio, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CG Oncology 0 0 8 1 3.11
Zura Bio 0 1 3 0 2.75

CG Oncology presently has a consensus target price of $63.88, indicating a potential upside of 77.88%. Zura Bio has a consensus target price of $17.33, indicating a potential upside of 295.74%. Given Zura Bio’s higher probable upside, analysts plainly believe Zura Bio is more favorable than CG Oncology.

Earnings and Valuation

This table compares CG Oncology and Zura Bio”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CG Oncology $200,000.00 12,044.21 -$48.61 million N/A N/A
Zura Bio N/A N/A -$69.24 million N/A N/A

CG Oncology has higher revenue and earnings than Zura Bio.

Institutional and Insider Ownership

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 22.1% of Zura Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

CG Oncology beats Zura Bio on 7 of the 10 factors compared between the two stocks.

About CG Oncology

(Get Free Report)

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

About Zura Bio

(Get Free Report)

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.